it is a biological shortage
GLP-1 Receptor Agonists Obesity Drugs Market Share The GLP-1 receptor agonists obesity drugs industry is primarily led by well-established companies, including: Novo Nordisk A/S (Denmark) Lilly (U.S.) Pfizer Inc
Figures were created with UCSF Chimera and ChimeraX, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with support from National Institutes of Health R01-GM129325 and the Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases
However, potential side effects include nausea, vomiting, diarrhea, abdominal pain, heartburn, constipation, or burping
The lemonade flavor is still tart, but the combination of natural flavors and stevia helps soften NAC's sharper edges
Current guidance from major nutrition societies recommends 1.2 to 2.0 grams of protein per kilogram of adjusted body weight per day during active weight loss on a GLP-1, paired with resistance training three days per week